Clinical trial
Efficacy and Safety of Grazax in Children
NCT00408616 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00408616 |
|---|---|
| Title | Efficacy and Safety of Grazax in Children |
| Official title | A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | Grazax-R, Grazax Placebo |
| Enrollment | 253 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Dec 7, 2006 |
| Last update posted | Mar 9, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: